Arvinas, INC.: management transactions · United States · SEC (Form 4)

About Arvinas, INC.

Arvinas, Inc. is a United States-based biopharmaceutical company listed on the NASDAQ under the ticker ARVN, with its headquarters in New Haven, Connecticut, United States. Founded in 2013, the company was built around a proprietary targeted protein degradation platform and is widely associated with PROTACs, or proteolysis targeting chimeras. Rather than merely inhibiting disease-driving proteins, Arvinas aims to eliminate them by leveraging the cell’s natural protein disposal machinery. This positions the company in one of the most innovative areas of modern drug discovery, spanning oncology and neurodegenerative disease. Arvinas is best described as a clinical-stage biotechnology company. It remains pre-commercial, with value creation driven primarily by research and development, clinical execution, and partnership economics rather than product sales. Its platform is designed to address high-value targets, including proteins historically considered difficult or impossible to drug with conventional small molecules. The company’s most visible programs include ARV-102, ARV-806, ARV-393, ARV-027, and ARV-6723, reflecting a pipeline that spans both oncology and neuroscience. Arvinas has also worked with major pharmaceutical partners, a model that can help defray development costs while broadening the long-term commercial opportunity for its technology. From a competitive standpoint, Arvinas holds a meaningful position in the emerging targeted protein degradation field. Its differentiation lies in the depth of its discovery engine, the scientific credibility of its platform, and its relative clinical lead in certain assets. The company has also highlighted that it has advanced at least one investigational drug through a pivotal trial and regulatory submission in the United States, which is an important validation point for a company still in the development stage. Geographically, Arvinas is primarily rooted in the United States, with operations centered in New Haven. That said, its platform and collaborations give it potential reach well beyond the domestic market, including Europe and other regions through licensing and partnership structures. For investors, the key takeaway is that Arvinas is a high-risk, high-upside biotechnology story whose valuation is likely to be driven by clinical readouts, regulatory milestones, partner activity, and capital allocation discipline. A recent highlight came in February 2026, when Arvinas reported fourth-quarter and full-year 2025 results and said it expected cash runway into the second half of 2028. Management also pointed to multiple potential value-driving milestones in 2026 across ARV-102, ARV-806, ARV-393, ARV-027, and ARV-6723. In addition, the company announced the appointment of Randy Teel, Ph.D., as President, CEO, and director. Separately, SEC Form 4 filings indicate continuing insider transaction activity, which market participants often watch closely in a company of this profile.